U.S. markets closed

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, BAX and MMSI

NEW YORK, NY / ACCESSWIRE / January 21, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Adamas Pharmaceuticals, Inc. (ADMS)

Investors Affected : August 8, 2017 - September 30, 2019

A class action has commenced on behalf of certain shareholders in Adamas Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/adamas-pharmaceuticals-inc-loss-submission-form/?id=5322&from=1

Baxter International Inc. (BAX)

Investors Affected : February 21, 2019 - October 23, 2019

A class action has commenced on behalf of certain shareholders in Baxter International Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) the Company lacked effective internal control over financial reporting; (3) as a result, the Company's financial statements were misstated and would likely require correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Defendants' statements about the Company's business and operations lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form/?id=5322&from=1

Merit Medical Systems, Inc. (MMSI)

Investors Affected : February 26, 2019 - October 30, 2019

A class action has commenced on behalf of certain shareholders in Merit Medical Systems, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/merit-medical-systems-inc-loss-submission-form/?id=5322&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770